1  Perioperative Management Concepts

Key Points
  • VTE prevention: Among most common preventable periop complications; requires systematic risk assessment & individualized mgmt
  • Anticoagulation mgmt: Critical for preventing both thrombosis & bleeding; timing of hold/restart individualized per risk
  • DOACs: Hold 24-72h preop
  • VKAs: Hold 3-5d before surgery; resume 12-24h postop (varies w/ bleeding risk)
  • Antiplatelet reversal: Type-dependent; aspirin often continued; clopidogrel/ticagrelor held 5-7d preop
  • Bridging heparin: Reserve for highest-risk patients only (recent VTE <3mo, mech valve, recent stroke)
    • Not routine (BRIDGE, PERIOP2 trials showed no benefit & ↑ bleeding)
  • Intraop/postop bleeding: Requires surgical team coordination; lab variability needs clinical context
  • Hematologist role: Personalize recommendations based on individual thrombotic vs bleeding risk

1.1 Introduction

  • Goal: Balance thrombosis prevention w/ bleeding risk
  • Multidisciplinary team: Heme, surgery, anesthesia, pharmacy, nursing
  • Hematologist role:
    • Assess operative status & anticoagulation risk
    • Determine med changes & timing
    • Monitor for complications
    • Communicate clearly w/ surgical team

1.2 Perioperative Venous Thromboembolism Prevention

1.2.1 Risk Stratification

  • VTE risk: Most common, easily preventable periop complication
  • Risk assessment: Use formal models to guide thromboprophylaxis decisions
  • Ortho surgery: Very high postop VTE risk → ASA or AC required
  • Most other surgeries: Low bleeding risk → AC can continue periop

1.2.2 Thrombotic Risk Categories

See Table 1-1 for detailed stratification by condition (VTE hx, AFib, mech valve)

Perioperative Thrombotic Risk
Risk Venous Thromboembolism Atrial Fibrillation Mechanical Heart Valve
High risk (>10%/mo for VTE or >5%/mo for AFib) Strong thrombophilia (protein C/S deficiency, antithrombin deficiency, homozygous FVL or PGM, double heterozygous FVL/PGM, multiple thrombophilic conditions), Antiphospholipid antibody syndrome (HITT w/ thrombosis), recent VTE (within 1 mo), thrombotic stroke, brain, gastric, esophageal cancer or myeloproliferative disorder) CHA₂DS₂-VASc score ≥5, Recent MI (<3 mo) HAVR w/o major stroke risk factor*
Moderate risk (4%-10%/mo for VTE or 4%-5%/mo for AFib) VTE w/in past 3-12 mo Recurrent VTE Non-strong thrombophilia (heterozygous FVL or PGM, Non-high-risk cancer a/w VTE) CHA₂DS₂-VASc score 3-4, Recurrent VTE HAVR w/o major stroke risk, Bileaflet AVR w/ major stroke risk factors*
Low risk (<4%/mo for VTE or <4% for AFib) VTE >12 mo ago CHA₂DS₂-VASc score 1-2 Bileaflet AVR w/o major stroke risk factors*

*Major stroke risk factors: AFib, prior stroke/TIA, prior valve thrombosis, diabetes, CHF, age >70 yr.

Adjusted from Douketis JD et al. Perioperative management of antithrombotic therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest 2012;141(2):e227S–e275S.

1.2.3 VKA Management

  • Preop: Hold 3-5d before surgery
  • Target INR: <2 preferred at surgery
  • Postop: Resume night of surgery if low bleeding risk
  • Time to therapeutic INR: 3-5d (long half-life)
  • Bridging heparin: NOT routine
    • BRIDGE trial: bridging w/ UFH/LMWH did NOT improve outcomes vs no bridging in VKA pts
    • PERIOP2: confirmed in higher-risk AFib/mech valve population
    • Same ↑ bleeding rates in both trials
    • Reserve bridging only for:
      • Recent VTE <3mo
      • Mech valve w/ thrombosis hx
      • Recent MI/stroke on chronic AC

1.2.4 Bridging Anticoagulation (if indicated)

  • Options:
    • UFH IV: 1 mg/kg SC 2× daily → can continue through periop window
    • LMWH: SC 2× daily
  • HIT-related special concern:
    • UFH & LMWH contraindicated
    • Alternatives: Lepirudin (direct thrombin inhibitor) or fondaparinux
    • Fondaparinux: Safe for HIT but long half-life → avoid preop (can’t reverse quickly)

1.2.5 VTE Mechanical Prophylaxis

  • Compression beneficial for high-risk pts
  • Sequential compression devices (SCDs) for:
    • Recent VTE <3mo
    • Mech mitral valve replacement
    • High thrombotic risk unable to take AC

1.3 Perioperative Anticoagulation Management

1.3.1 DOAC Perioperative Dosing

  • Hold duration: 24-72h preop (varies by drug & renal function)
  • Apixaban/rivaroxaban (Xa inhibitors):
    • Normal renal fxn: 24-48h
    • CrCl ↓: 48-72h
  • Dabigatran (direct thrombin inhibitor):
    • Normal renal fxn: 24-48h
    • CrCl ↓: 48-72h
  • Edoxaban: 24-48h (depends on indication)
  • Resume: Earliest 12-24h postop if hemostasis stable

1.3.2 Drug-Specific Perioperative Protocols

  • Individualize based on:
    • Procedure bleeding risk
    • Patient thrombotic risk
    • Renal function
    • Institutional protocols
  • Shared decision-making essential for all high-risk decisions

1.4 Antiplatelet Management

1.4.1 General Principles

  • Depends on:
    • Procedure type & bleeding risk
    • Indication for drug (atherothrombotic vs thrombotic)
    • Timing of past thrombotic events (eg, PCI for MI)
    • Pharmacologic properties (reversible vs irreversible inhibition)

1.4.2 Aspirin

Clinical Pearl: Aspirin Continuation
  • Most procedures: Continue periop
  • Decision based on:
    • Underlying thrombotic risk (low vs mod vs high)
    • Surgical bleeding risk (low vs high)
    • Renal function
  • Low/moderate thrombotic risk + low bleeding risk: Safe to continue
  • Mechanism: Irreversible platelet inhibition → effects persist 7-10d
  • Preop: Generally continued unless high bleeding risk procedure
  • Postop: Resume when bleeding risk acceptable

1.4.3 P2Y₁₂ Inhibitors (Clopidogrel, Prasugrel, Ticagrelor)

  • Hold duration preop:
    • Clopidogrel: 5d
    • Prasugrel: 7d
    • Ticagrelor: 5-7d
  • Resume: 12-24h postop if hemostasis acceptable
  • Special situations:
    • Recent ACS w/ PCI: Defer elective surgery if possible
    • Bare metal stent: Minimum 1mo DAPT before surgery
    • Drug-eluting stent: Minimum 3-6mo DAPT per guidelines
  • Multidisciplinary discussion essential to balance ischemic vs bleeding risk

1.4.4 Minor Procedures (Dental, Dermatologic, Ophthalmologic)

  • Brief interruption often sufficient
  • Aspirin: Usually continued
  • P2Y₁₂ inhibitors: May hold 5-7d if bleeding risk

1.5 Intraoperative & Postoperative Bleeding Management

1.5.1 General Approach

  • Comprehensive assessment needed for anticoagulation reversal decisions
    • NOT always possible in emergency/urgent surgery
    • Lab testing may not be timely enough for emergent guidance
  • Supportive care first: Fluids, transfusion support when appropriate
  • Reversal agents: Reserved for life-threatening bleeding

1.5.2 Laboratory Testing for Hemostasis

  • Traditional tests:
    • PT/INR: Assesses VKA effect
    • aPTT: Assesses UFH effect (less useful for DOAC/VKA)
    • Thrombin time: Can suggest DOAC presence
    • Platelet count & fibrinogen
  • Viscoelastic assays (TEG, ROTEM): Whole-blood hemostasis assessment
    • Role in emergent surgery NOT established
    • NOT advised for routine emergent assessment
  • Platelet function testing: NOT routinely advised
    • Lack of evidence for emergent hemostasis guidance
    • Don’t guide transfusion decisions

1.5.3 DOAC-Specific Assays

  • Calibrated anti-Xa assays: Quantify factor Xa inhibitor levels (apixaban, rivaroxaban, edoxaban)
  • Dilute thrombin time: Detects dabigatran presence
    • Activity NOT well linked to clinical outcomes
    • Not broadly available
  • Use case: May help guide reversal decisions in life-threatening bleeding
Clinical Pearl: Bleeding Assessment
  • DOAC-related life-threatening bleeding:
    • Lab assays may help guide risk assessment
    • Consider anticoagulant type, timing of last dose, renal function
    • Clinical context (severity, site of bleed) guides reversibility decisions

1.5.4 Anticoagulation Reversal

1.5.4.1 VKA (Warfarin)

  • Life-threatening bleeding:
    • 4F-PCC (prothrombin complex concentrate) + IV vitamin K
    • 4F-PCC preferred over FFP (faster, smaller volume)
    • Vitamin K: 10 mg IV (slow, peaks in 12-24h)
  • Non-life-threatening: Vitamin K alone; hold warfarin; consider bridging if high thrombotic risk

1.5.4.2 DOAC

  • Dabigatran (direct thrombin inhibitor):
    • Life-threatening bleeding: Idarucizumab (specific reversal agent)
      • Dose: 5g IV (fixed, not weight-based)
      • Rapid reversal (minutes)
    • Alternative: 4F-PCC (less specific) or hemodialysis (if delay acceptable & high-dose dialysis available)
  • Apixaban, Rivaroxaban, Edoxaban (Xa inhibitors):
    • Life-threatening bleeding: Andexanet α (specific reversal agent)
      • Bolus dosing based on last DOAC dose & timing
      • Rapid reversal
    • Alternatives: 4F-PCC (less specific) if andexanet unavailable
    • Fresh frozen plasma: NOT effective

1.5.4.3 UFH

  • Immediate reversal: Protamine sulfate
    • Dose: 1 mg per 100 units UFH IV (max ~50mg/dose)
    • Give slowly IV (risk of anaphylaxis if rapid)

1.5.4.4 LMWH

  • Partial reversal: Protamine sulfate
    • Dose: 1 mg per 1mg enoxaparin (less effective than for UFH)
  • Incomplete reversal: Only ~60% of anti-Xa activity reversed

1.5.4.5 Heparin-Induced Thrombocytopenia (HIT)

  • Management periop:
    • UFH & LMWH contraindicated (risk of thrombosis/worsening)
    • Bridging alternatives:
      • Lepirudin (direct thrombin inhibitor)
      • Fondaparinux (though long half-life limits preop use)
    • Decision-making: Multidisciplinary discussion needed on timing, reversibility

1.5.5 Institutional Protocols

  • Essential: Standardized bleeding response protocols
    • Ensure evidence-based therapy
    • Reduce low-value care
    • Team communication & coordination

1.6 Conclusion

  • Perioperative anticoagulation: Complex; requires individualized approach
  • Risk assessment: Integrate patient thrombotic risk + procedural bleeding risk + urgency
  • Hematologist role:
    • Personalize recommendations
    • Communicate clearly w/ surgical team
    • Participate in multidisciplinary planning
    • Understand role within broader team
  • Key principle: No one-size-fits-all; each pt & procedure unique

1.7 Bibliography

Anderson DR, Morgani GD, Bemment C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical patients. Blood Adv. 2019;3(23):3898–3944.

Arebi YM, Al-Hameed H, Buhrer REA et al. A Adjunctive Intermittent Pneumatic Compression and Early Mobilization for Prevention of Venous Thromboembolism After Orthopedic Surgery. N Engl J Med. 2013;368(15):1471.

Babangoli MI, Al-Shahi Salman R, Cendander C, et al. PATCH trial-exploratory analysis. Blood Adv. 2018;2(15):1901–1908.

Barnes GD, Gage KA, Friedich JH. Perioperative management of oral anticoagulants: A focus on recent trials & innovations. Hap Post Agg. 2014;23(2):62–67.

Barron AE, Ruggles N, Keen S. Perioperative consultative hematology: can we clear my patient for a procedure? Hematology Am Soc Hematol Educ Program. 2018;2018:123–135.

Chung KL, Douketis JD. Optimal oral anticoagulation dosing in patients with atrial fibrillation and chronic kidney disease. Clin Card J Lab Med. 2013;33(10):343.

Cutter A, Arnold CDL, Tuli D, et al. Revised update of atrial fibrillation guidelines from the Anticoagulation Forum. Am J Hematol. 2019;94(6):601–610.

Dogart WE, Ansell J, Rees CD, et al. “Reduce the likelihood of patient harm associated with use of anticoagulant therapy”. Transfusion. 2012;52(4):695–701; quiz 694. doi:10.1111/j.1537–2995.2011.03282.x

Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative management of patients w/ atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2019;179(11):1469–1478.

Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients w/ atrial fibrillation. N Engl J Med. 2015;373(9):823–833.

Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative management of patients w/ atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2019;179(11):1469–1478.

Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022;162(5):e207–e243.

Falck-Ytter Y, Francis CW, Jonasson T, Ortel T. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy & Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guideline. Chest. 2012;141(2 Suppl):e227S–e275S.

Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy & Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guideline. Chest. 2012;141(2 Suppl):e227S–e275S.

Heit JA, Falck-Ytter Y, Beyer J. American Society of Regional Anesthesia & Pain Medicine Evidence-Based Clinical Practice Guideline (4th Edition). Reg Anesth Pain Med. 2018;43(3):263–309.

Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336(21):1506–1511.

Kovacs MJ, Wells PS, Anderson DJR, et al. Postoperative low-molecular-weight heparin prophylaxis in patients at high risk of arterial thromboembolism. PERIOP2: double blind randomized controlled trial. BMJ. 2021;373:n1025.

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272.

Perez-Rivera JA, Monagle-Campio T, Criezu-Borella C, RuizPerez P. Pharmacokinetic drug evaluation of vqavasqr for secondary prevention after acute coronary syndrome. Expert Opin Drug Metab. 2017;13(3):329–350.

Porres-Aguilar M, Ansell J, Mukherjee D, et al. Impact of hospital-based multidisciplinary anticoagulation stewardship programs. Arch Med Res. 2023;54(1):1–6.

Samuelson BT, Cuker A. Measurement & reversal of the direct oral anticoagulants. Blood. 2017;3(10):77–84.

Sarode R. How do I transfuse platelets to reverse anti-PLT drug effect? Transfusion. 2012;52(4):695–701.quiz 694. doi:10.1111/j.1537–2995.2011.03282.x

Spyropoulos AC, Brohi K, Caprini J, et al. Scientific & Standardization Committee Communication: Guidance document on the perioperative management of patients on chronic oral anticoagulation therapy: recommendations for standardized reporting of procedural/surgical blood risk & patient-specific thromboembolism risk. J Thromb Haemost. 2019;17(11):1966–1972.

Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulation: a Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(5):594–622.

Zakko L, Rustagi T, Douglas M, Lane L. No benefit from platelet transfusion for gastrointestinal bleeding in patients taking antiplatelet agents. Clin Gastroenterol Hepatol. 2017;15(1):46–52.